NeurogesX Inc (NGSX.PK)
NGSX.PK on OTC Markets Group
0.01USD
1 Aug 2013
0.01USD
1 Aug 2013
Price Change (% chg)
$0.00 (+31.67%)
$0.00 (+31.67%)
Prev Close
$0.01
$0.01
Open
$0.01
$0.01
Day's High
$0.01
$0.01
Day's Low
$0.01
$0.01
Volume
188,699
188,699
Avg. Vol
70,694
70,694
52-wk High
$0.41
$0.41
52-wk Low
$0.01
$0.01
About
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pains management therapies to address unmet medical needs. Qutenza is the Company's first commercial product, available in the United States and in certain European countries. Qutenza is a... (more)
No analyst recommendations are available for NGSX.PK.
Overall
| Beta: | 2.15 |
| Market Cap (Mil.): | $0.26 |
| Shares Outstanding (Mil.): | 33.33 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| NGSX.PK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 38.06 | 37.87 |
| EPS (TTM): | -0.98 | -- | -- |
| ROI: | -189.10 | 19.42 | 18.70 |
| ROE: | -- | 20.10 | 19.53 |
Competitors
| Price | Change | |
|---|---|---|
| Dainippon Sumitomo Pharma Co., Ltd. (4506.T) | ¥1,387 | +56.00 |
| Pfizer Inc. (PFE.N) | $29.33 | +0.22 |
| Novo Nordisk A/S (NOVOb.CO) | kr.968.00 | -7.00 |
| Novartis AG (NOVN.VX) | CHF67.55 | +0.95 |
| AstraZeneca plc (AZN.L) | 3,332.50p | -1.50 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | 0.00 |
| Eli Lilly & Co. (LLY.N) | $53.81 | +0.31 |
| Bristol Myers Squibb Co. (BMY.N) | $43.84 | -0.15 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
| UCB SA (UCB.BR) | €45.99 | +1.75 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: S&P Capital IQ Quantitative Report
|
$58.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

